Lily Yin Weckx

Universidade Federal de São Paulo

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Maria Isabel de Moraes‐Pinto

Universidade Federal de São Paulo

Alessandra R. Souza

Universidade Federal de São Paulo

Amélia Miyashiro Nunes dos Santos

Universidade Federal de São Paulo

Teresa Lambe

University of Oxford

Sagida Bibi

Oxford BioMedica (United Kingdom)

Parvinder K. Aley

University of Oxford

Andrew J. Pollard

University of Oxford

Sue Ann Costa Clemens

University of Oxford

Marco Aurélio Palazzi Sáfadi

Faculdade de Ciências Médicas da Santa Casa de São Paulo

Renato de Ávila Kfouri

Sociedade Brasileira de Pediatria

Cooperative Institutions

University of Oxford

382

Jenner Institute

162

Universidade Federal de São Paulo

156

Oxford BioMedica (United Kingdom)

145

National Institute for Health Research

Universidade de São Paulo

Churchill Hospital

GlaxoSmithKline (Belgium)

Public Health England

University College London

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Yellow Fever Vaccine (YFV) for Patients with Egg Allergy: Protocol Proposal.

Journal of Allergy and Clinical Immunology (2019)

Barbara Luiza B Cancado Carolina Sánchez Aranda Alessandra R. Souza Lily Yin Weckx Márcia C. Mallozi

Yellow fever vaccine

10.1016/j.jaci.2018.12.695

Cite

Citations (4)

Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis

International Journal of Pediatric Otorhinolaryngology (2016)

Juliana Sato Hermann Lily Yin Weckx J M Nurmberger Gildo Santos Antônio Carlos Campos Pignatari

Recurrent Respiratory Papillomatosis

Papillomatosis

10.1016/j.ijporl.2016.01.032

Cite

Citations (41)

Twenty-four-hour esophageal pH monitoring in children and adolescents with chronic and/or recurrent rhinosinusitis

Brazilian Journal of Medical and Biological Research (2005)

Vítor Monteiro V.L. Sdepanian Lily Yin Weckx U Fagundes–Neto Mauro Batista de Morais

Gastroesophageal reflux (GER) disorder was studied in children and adolescents with chronic and/or recurrent rhinosinusitis not associated with bronchial asthma. Ten children with a clinical and radiological diagnosis of chronic and/or recurrent rhinosinusitis, consecutively attended at the Pediatric Otolaryngology Outpatient Clinic, Federal University of São Paulo, were evaluated. Prolonged esophageal pH monitoring was used to investigate GER disorder. The mean age of the ten patients evaluated (eight males) was 7.4 ± 2.4 years. Two patients presented vomiting as a clinical manifestation and one patient presented retrosternal pain with a burning sensation. Twenty-four-hour esophageal pH monitoring was performed using the Sandhill apparatus. An antimony probe electrode was placed in the lower third of the esophagus, confirmed by fluoroscopy and later by a chest X-ray. The parameters analyzed by esophageal pH monitoring included: total percent time of the presence of acid esophageal pH, i.e., pH below 4 (<4.2%); total number of acid episodes (<50 episodes); number of reflux episodes longer than 5 min (3 or less), and duration of the longest reflux episode (<9.2 min). One patient (1/10, 10%) presented a 24-h esophageal pH profile compatible with GER disorder. This data suggest that an association between chronic rhinosinusitis not associated with bronchial asthma and GER disorder may exist in children and adolescents, especially in those with compatible GER disorder symptoms. In these cases, 24-h esophageal pH monitoring should be performed before indicating surgery, since the present data suggest that 10% of chronic rhinosinusitis surgeries can be eliminated.

Esophageal pH monitoring

Chronic Cough

10.1590/s0100-879x2005000200009

Cite

Citations (20)

Safe administration of rotavirus vaccine in a cohort of infants exposed to immunosuppressive drugs during gestation

Transplant Infectious Disease (2018)

Maria Isabel Saraiva Dinelli Amélia Miyashiro Nunes dos Santos Lily Yin Weckx Maria Isabel de Moraes‐Pinto

In utero exposure to immunosuppressive drugs might be a contraindication to rotavirus vaccine, but that may vary according to the immunosuppressive regimen. We evaluated 24 infants born to kidney transplanted mothers exposed to 3 immunosuppressants during pregnancy (prednisone, azathioprine, and tacrolimus or cyclosporine) and 31 control infants not exposed to these medications. No differences in adverse events were detected after rotavirus vaccination at 2 and 4 months.

Contraindication

Rotavirus vaccine

Regimen

10.1111/tid.12951

Cite

Citations (14)

Prevalência de anticorpos contra o vírus da hepatite A em crianças e adolescentes expostos e/ou infectados pelo HIV

Jornal de Pediatria (2005)

Aída F. T. B. Gouvêa Maria Isabel de Moraes‐Pinto Daisy Maria Machado Fabiana Bononi do Carmo Suênia Cordeiro de Vasconcelos Beltrão

OBJETIVO: Avaliar a prevalência de anticorpos contra o vírus da hepatite A em crianças e adolescentes expostos e/ou infectados pelo HIV. MÉTODOS: Entre setembro de 1996 e agosto de 2002, foram incluídos neste estudo 352 crianças e adolescentes, filhos de mães soropositivas para o HIV (200 expostos e não-infectados pelo HIV, e 152 expostos e infectados pelo HIV). Essas crianças e adolescentes, com idade entre 1 e 14 anos, acompanhados no Ambulatório de AIDS Pediátrica da Universidade Federal de São Paulo (UNIFESP), fizeram teste sorológico contra hepatite A como parte da avaliação de rotina. A dosagem de anticorpos anti-HAV (anticorpos totais e IgM) foi realizada através do método ELISA (Dia Sorin e Radim). A comparação das faixas etárias entre os grupos foi feita utilizando o teste do qui-quadrado e, para comparar as médias de idade das categorias clínicas entre as crianças infectadas, utilizou-se o teste t. RESULTADOS: A prevalência de anticorpos contra o vírus da hepatite A foi de 34% nos pacientes infectados e expostos ao HIV e 19,7% no grupo de soro-revertidos (expostos ao HIV e não-infectados). Estratificando a amostra por faixa etária, observamos que, para as crianças de 2 a 10 anos, o grupo de infectados pelo HIV apresentou prevalência de anticorpos para o vírus hepatite A (35,5%) maior do que o grupo de soro-revertidos (16,7%) (p = 0,005). Dentro do grupo de infectados pelo HIV, estratificando a amostra em relação à categoria clínica da infecção pelo HIV, observamos que as crianças pertencentes às categorias B e C apresentaram prevalência de anticorpos para o vírus da hepatite A maior (40,5%) do que aquelas pertencentes às categorias N e A (24,1%) (p = 0,042), apesar de apresentarem média de idade sem diferença estatística: 5,66 anos para as categorias N e A e 5,18 anos para as categorias B e C (p = 0,617). CONCLUSÕES: A prevalência de anticorpos contra o vírus da hepatite A na população de crianças e adolescentes infectados e/ou expostos ao HIV na faixa etária de 1 a 14 anos foi de 26%. Considerando-se a possibilidade de agravamento da infecção pelo HIV quando associada à infecção pelo vírus da hepatite A, sugerimos a profilaxia vacinal nesse grupo de indivíduos.

10.1590/s0021-75572005000400006

Cite

Citations (5)

Controvérsias em imunizações: 2006

Lily Yin Weckx Renato de Ávila Kfouri Vicente Amato Neto

Source

Cite

Citations (0)

Hepatitis B: prevalence of anti-HBc marker and seroconvertion after immunization among Brazilian indigenous population

Journal of Hepatology (2002)

Ramiro Anthero de Azevedo Bettina Grajcer Lily Yin Weckx A.E.B. Silva Daleth Rodrigues

Hepatitis B

10.1016/s0168-8278(02)80790-5

Cite

Citations (0)

CLINICAL MANAGEMENT OF LOCALIZED BCG ADVERSE EVENTS IN CHILDREN

Revista do Instituto de Medicina Tropical de São Paulo (2016)

Thais das Neves Fraga Moreira Maria Isabel de Moraes‐Pinto Beatriz Tavares Costa‐Carvalho Anete Sevciovic Grumach Lily Yin Weckx

SUMMARY BCG adverse events (BCG-AE) are rare conditions with no well-established treatment. This study aims to describe clinical characteristics and outcome of localized BCG-AE. Children with BCG-AEs who were treated at the Reference Center for Special Immunobiologicals of the Federal University of São Paulo from 2009 to 2011 were included. Patients were followed monthly until 3 months after healing. One hundred and twenty-seven patients with localized BCG-AE were followed: 67 (52.7%) had suppurative lymphadenitis; 30 (23.6%) injection-site abscess; five (3.9%) had enlarged lymph node > 3 cm; four (3.1%) had ulcer > 1 cm; and one (0.8%) had a local bacterial infection. Five patients (3.9%) had more than one BCG-AE simultaneously. Fifteen patients (11.8%) had atypical manifestations: seven wart-like lesions; five BCG reactivations; two other dermatologic lesions and one with vasomotor phenomenon. Isoniazid was used in 96 patients with typical BCG-AE (85.7%) until lesion resolution which took place 3.1 months later (in median); the healing rate was 90.6%. Patients with atypical manifestations had an individual approach. Regarding the outcome, 105/112 patients with typical AE and 13/15 patients with atypical AE had resolution of BCG-AE. Localized BCG-AE caused by BCG Moreau RJ had positive outcome when treated with a short course of isoniazid. Atypical BCG-AE are not infrequent.

10.1590/s1678-9946201658084

Cite

Citations (18)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Nature Communications (2021)

Sue Ann Costa Clemens Pedro M. Folegatti Katherine R. W. Emary Lily Yin Weckx Jeremy Ratcliff

Abstract Several COVID-19 vaccines have shown good efficacy in clinical trials, but there remains uncertainty about the efficacy of vaccines against different variants. Here, we investigate the efficacy of ChAdOx1 nCoV-19 (AZD1222) against symptomatic COVID-19 in a post-hoc exploratory analysis of a Phase 3 randomised trial in Brazil (trial registration ISRCTN89951424). Nose and throat swabs were tested by PCR in symptomatic participants. Sequencing and genotyping of swabs were performed to determine the lineages of SARS-CoV-2 circulating during the study. Protection against any symptomatic COVID-19 caused by the Zeta (P.2) variant was assessed in 153 cases with vaccine efficacy (VE) of 69% (95% CI 55, 78). 49 cases of B.1.1.28 occurred and VE was 73% (46, 86). The Gamma (P.1) variant arose later in the trial and fewer cases ( N = 18) were available for analysis. VE was 64% (−2, 87). ChAdOx1 nCoV-19 provided 95% protection (95% CI 61%, 99%) against hospitalisation due to COVID-19. In summary, we report that ChAdOx1 nCoV-19 protects against emerging variants in Brazil despite the presence of the spike protein mutation E484K.

2019-20 coronavirus outbreak

Betacoronavirus

10.1038/s41467-021-25982-w

Cite

Citations (47)

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

The Lancet (2021)

Merryn Voysey Sue Ann Costa Clemens Shabir A. Madhi Lily Yin Weckx Pedro M. Folegatti

The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks. The planned roll-out in the UK will involve vaccinating people in high-risk categories with their first dose immediately, and delivering the second dose 12 weeks later. Here, we provide both a further prespecified pooled analysis of trials of ChAdOx1 nCoV-19 and exploratory analyses of the impact on immunogenicity and efficacy of extending the interval between priming and booster doses. In addition, we show the immunogenicity and protection afforded by the first dose, before a booster dose has been offered.

Booster dose

Regimen

10.1016/s0140-6736(21)00432-3

Cite

Citations (1,139)